Allo-HSCT ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 20 | Adrenoleukodystrophy | 1 |
20. Adrenoleukodystrophy
Clinical trials : 61 / Drugs : 90 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 126
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02204904 (ClinicalTrials.gov) | April 2015 | 28/7/2014 | Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD) | A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males =17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy | X-Linked Adrenoleukodystrophy (X-ALD);Cerebral Adrenoleukodystrophy (CALD);Adrenoleukodystrophy (ALD) | Genetic: Allo-HSCT | bluebird bio | NULL | Terminated | N/A | 17 Years | Male | 59 | United States;Argentina;Canada;Germany;Italy;Netherlands;United Kingdom |